Michael Horberg, MD, MAS, FACP, FIDSA

Michael Horberg

Michael Horberg, MD, MAS, FACP, FIDSA

Executive Director Research, MAPMG and MAPRI
301-816-6302
Michael.Horberg@kp.org

Education:

MD, Boston University School of Medicine, Boston, MA, 1985
MAS, University of California San Francisco, San Francisco, CA, 2006
BA, Boston University, Boston, MA, 1985
Residency, Categorical Internal Medicine, Michael Reese Hospital/University of Chicago, Chicago, IL
1985-1988

Academic Affliations:

Clinical Assistant Professor (Affiliated) of Medicine (Infectious Diseases), Stanford University Medical School, Palo Alto, CA

Professional Affliations:

Chair, HIV Medicine Association
Fellow, American College of Physicians
Fellow, Infectious Disease Society of America
Past President, Gay and Lesbian Medical Association

Michael Alan Horberg, MD, MAS, FACP is Executive Director Research and Community Benefit of Mid-Atlantic Permanente Medical Group (MAPMG) and the director of the Mid-Atlantic Permanente Research Institute (MAPRI). He is also director of HIV/AIDS for Kaiser Permanente.

Dr. Horberg has been appointed to serve on the Presidential Advisory Council on HIV/AIDS (PACHA), and co-chairs the Access to Care and Improved Outcomes Committee of PACHA. Dr. Horberg is a Fellow of the American College of Physicians, and he presently serves as Vice-Chair of the Board of Directors of the HIV Medicine Association of the Infectious Disease Society of America. He has co-chaired the NCQA/AMA/HRSA/IDSA sponsored Expert Panel on HIV-related provider performance measures. He is Assistant Clinical Professor at Stanford University Medical School. Dr. Horberg is past-president of the national Gay and Lesbian Medical Association.

His HIV research interests are health service outcomes for HIV-infected patients (including HIV quality measures and care improvement, and determinants of optimized multidisciplinary care for maximized HIV outcomes), medication adherence issues in these patients, and epidemiology of the disease.

He graduated from Boston University’s College of Liberal Arts and School of Medicine (with honors of Summa cum Laude and Phi Beta Kappa) and completed his internal medicine residency at Michael Reese Hospital in Chicago (University of Chicago affiliate). He received his Master of Advanced Studies (Clinical Research) from University of California San Francisco.

Research Interests:

HIV/AIDS:

  • Models of Care
  • HIV Care and Outcomes Quality Metrics
    • Registry Development
  • Pharmaceutical Safety and Comparative Effectiveness

Sexually Transmitted Disease:

  • Gay/Lesbian Health and STI risk
  • Syphilis

Hepatitis:

  • Registry Development
  • Hepatitis Care Quality Metrics

  1. Yehia B, Rebeiro P, Athoff K, Agwu A, Horberg M, Samji H, Napravnik S, Mayer K, Buchacz K, Tedaldi E, Silverberg M, Thorne J, Burchell A, Rourke S, Rachlis A, Mayor A, Gill J, Zinski A, Ohl M, Anastos K, Abraham AG, Moore R, Gange S, Gebo K. The impact of age on retention in care and viral suppression. J Acquir Immune Defic Syndr. 2014 Dec 31 (Epub ahead of print).
    PubMed abstract
  2. Marcus J, Leyden W, Chao C, Chow F, Horberg M, Hurley L, Klein D, Quesenberry C, Towner W, Silverberg M. HIV infection and incidence of ischemic stroke. JAMA Internal Medicine. 2014 June 17 [Epub ahead of print].
    PubMed abstract
  3. DeLorenze G, Tsai A-L, Horberg M, Quesenberry C. Cost of care for HIV-infected patients with co-occurring substance use disorder or psychiatric disease: report from a large, integrated health plan. AIDS Research and Treatment. 2014 June 22 [Epub ahead of print].
    PubMed abstract
  4. Marcus J, Chao C, Leyden W, Xu L, Klein D, Horberg M, Towner W, Quesenberry C, Van den Eeden SK, Silverberg M. Prostate Cancer Incidence and Prostate-Specific Antigen Testing among HIV-Positive and HIV-Negative Men. JAIDS.  2014 May 12 (Epub ahead of print).
    PubMed abstract
  5. Linas B, Hu H, Carter D, Horberg M. Hepatitis C screening trends in a large integrated health system. American Journal of Medicine. 2014:127(5):398-405.
    PubMed abstract
  6. Silverberg MJ, Leyden WA, Xu L, Horberg MA, Chao CR, Towner WJ, Hurley LB, Quesenberry CP, Jr., Klein DB. Immunodeficiency and risk of myocardial infarction among HIV-positive individuals with access to care. J Acquir Immune Defic Syndr. Feb 1 2014;65(2):160-166.
    PubMed abstract
  7. Aberg JA, Gallant JE, Ghanem KG, Emmanuel P, Zingman BS, Horberg MA. Primary care guidelines for the management of persons infected with HIV: 2013 Update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. Jan 2014;58(1):1-10.
    PubMed abstract
  8. Abraham AG, Althoff KN, Jing Y, Estrella M, Kitahata M, Wester W, Bosch R, Crane H, Eron J, Gill J, Horberg M, Justice A, Klein D, Krishnasami Z, Mayor A, Moore R, Palella F, Parikh C, Silverberg M, Golub E, Jacobson L, McKaig R, Napravnik S, Rodriguez B, Lucas G. End stage renal disease among HIV-infected adults in North America. Clinical Infectious Diseases. Nov 2014 19 (Epub ahead of print).
    PubMed abstract
  9. Maeda J, Lee K, Horberg M. Comparative Health Systems Research among Integrated Delivery Systems and Managed Care Organizations: A Systematic Review. Permanente Medical Journal. 2014 Summer; 18(3):66-77.
    PubMed abstract
  10. Althoff KN, Rebeiro P, Brooks JT, Buchacz K, Gebo K, Martin J, Hogg R, Thorne JE, Klein M, Gill MJ, Sterling TR, Yehia B, Silverberg MJ, Crane H, Justice AC, Gange SJ, Moore R, Kitahata MM, Horberg MA. Disparities in the quality of HIV care when using US Department of Health and Human Services indicators. Clin Infect Dis. Apr 2014;58(8):1185-1189.
    PubMed abstract
  11. Rebeiro P, Horberg M, Gange S, Gebo K, Yehia B, Brooks JT, Buchacz K, Silverberg M, Gill J, Moore R, Althoff KN. Strong agreement between alternative HIV clinical retention indicators from the Institute of Medicine and the Department of Health and Human Services: A cross-sectional study. Population Health Metric. 2013 (Submitted).
  12. Tran TN, Ray GT, Horberg M. Complications of herpes zoster in cancer patients. Scandinavian Journal of Infectious Diseases. Jul 2014;46(7):528-32.
    PubMid abstract
  13. Miller V, Horberg M. Getting to normal: are we there yet? AIDS. Mar 27 2013;27(6):1027-1028.
    PubMed abstract
  14. Mayer K, Gazzard B, Zuniga JM, Amico KR, Anderson J, Azad Y, Cairns G, Dedes N, Duncombe C, Fidler SJ, Granich R, Horberg MA, McCormack S, Montaner JS, Rees H, Schackman B, Sow PS. Controlling the HIV epidemic with antiretrovirals: IAPAC consensus statement on treatment as prevention and preexposure prophylaxis. J Int Assoc Provid AIDS Care. May-Jun;12(3):208-216.
    PubMed abstract
  15. Meenan R, Horberg M, Silverberg M, Chun C, Williams A, McBurnie M, Keast E, Leyden W, Xu L, Vijayadeva V, Antoniskis D. PS2-20: Developing new quality measures for HIV care using the electronic medical record. Clinical Medicine and Research. 2013;11 (3):160.
    PubMed abstract
  16. Hanna DB, Buchacz K, Gebo KA, Hessol NA, Horberg MA, Jacobson LP, Kirk GD, Kitahata MM, Korthuis PT, Moore RD, Napravnik S, Patel P, Silverberg MJ, Sterling TR, Willig JH, Collier A, Samji H, Thorne JE, Althoff KN, Martin JN, Rodriguez B, Stuart EA, Gange SJ. Association between U.S. state AIDS Drug Assistance Program (ADAP) features and HIV antiretroviral therapy initiation, 2001-2009. PLoS One. 2013;8(11):e78952.
    PubMed abstract
  17. Horberg MA, Hurley LB, Silverberg MJ, Klein DB, Quesenberry CP, Mugavero MJ. Missed office visits and risk of mortality among HIV-infected subjects in a large healthcare system in the United States. AIDS Patient Care STDS. Aug 2013;27(8):442-449.
    PubMed abstract
  18. Ralston JD, Silverberg MJ, Grothaus L, Leyden WA, Ross T, Stewart C, Carzasty S, Horberg M, Catz SL. Use of web-based shared medical records among patients with HIV. Am J Manag Care. 2013;19(4):e114-124.
    PubMed abstract
  19. Hanna DB, Buchacz K, Gebo KA, Hessol NA, Horberg MA, Jacobson LP, Kirk GD, Kitahata MM, Korthuis PT, Moore RD, Napravnik S, Patel P, Silverberg MJ, Sterling TR, Willig JH, Lau B, Althoff KN, Crane HM, Collier AC, Samji H, Thorne JE, Gill MJ, Klein MB, Martin JN, Rodriguez B, Rourke SB, Gange SJ. Trends and Disparities in Antiretroviral Therapy Initiation and Virologic Suppression Among Newly Treatment-Eligible HIV-Infected Individuals in North America, 2001-2009. Clin Infect Dis. Apr 2013;56(8):1174-1182.
    PubMed abstract
  20. Habel LA, Ray GT, Silverberg MJ, Horberg M, Yawn BP, Castillo A, Quesenberry CP, Jr., Li Y, Saddier P, Tran TN. The Epidemiology of Herpes Zoster in Patients with Newly Diagnosed Cancer. Cancer Epidemiol Biomarkers Prev. Jan 2013:22(1):82-90.
    PubMed abstract
  21. Justice AC, Modur SP, Tate JP, Althoff KN, Jacobson LP, Gebo KA, Kitahata MM, Horberg MA, Brooks JT, Buchacz K, Rourke SB, Rachlis A, Napravnik S, Eron J, Willig JH, Moore R, Kirk GD, Bosch R, Rodriguez B, Hogg RS, Thorne J, Goedert JJ, Klein M, Gill J, Deeks S, Sterling TR, Anastos K, Gange SJ. Predictive accuracy of the Veterans Aging Cohort Study index for mortality with HIV infection: a North American cross cohort analysis. J Acquir Immune Defic Syndr. Feb 1 2013 62(2):149-163.
    PubMed abstract
  22. Delorenze GN, Horberg MA, Silverberg MJ, Tsai A, Quesenberry CP, Baxter R. Trends in annual incidence of methicillin-resistant Staphylococcus aureus (MRSA) infection in HIV-infected and HIV-uninfected patients. Epidemiol Infect. 2013;141(11):2392-402.
    PubMed abstract
  23. Horberg M, Raymond B. Financial policy issues for HIV pre-exposure prophylaxis: Cost and access to insurance. American Journal of Preventative Medicine. Jan 2013;44(1 Suppl 2):S125-8.
    PubMed Abstract
  24. Rebeiro P, Althoff KN, Buchacz K, Gill J, Horberg M, Krentz H, Moore R, Sterling TR, Brooks JT, Gebo KA, Hogg R, Klein M, Martin J, Mugavero M, Rourke S, Silverberg MJ, Thorne J, Gange SJ. Retention among North American HIV-infected persons in clinical care, 2000-2008. J Acquir Immune Defic Syndr. Mar 1 2013;62(3):356-362.
    PubMed abstract
  25. Horberg MA, Hurley LB, Towner WJ, Allerton MW, Tang BT, Catz SL, Silverberg MJ, Quesenberry CP. Influence of provider experience on antiretroviral adherence and viral suppression. HIV AIDS (Auckl). 2012;4:125-133.
    PubMed abstract
  26. Althoff KN, Buchacz K, Hall H, Zhang J, Hanna D, Rebeiro P, Gange S, Moore RD, Kitahata M, Gebo K, Martin J, Justice A, Horberg M, Hogg R, Sterling T, Cescon A, Klein M, Thorne J, Crane HM, Mugavero M, Napravnik S, Kirk G, Jacobson L, Brooks JT. Trends in Antiretroviral Therapy Use, HIV RNA Plasma Viral Loads and CD4 T-Lymphocyte Counts among HIV-Infected Persons in Care in the United States, 2000-2008. Ann Intern Med. Sep 4 2012;157(5):325-335.
    PubMed abstract
  27. Chao C, Leyden WA, Xu L, Horberg MA, Klein D, Towner WJ, Quesenberry CP, Jr., Abrams DI, Silverberg MJ. Exposure to antiretroviral therapy and risk of cancer in HIV-infected persons. AIDS. Nov 2012;26(17):2223-2231.
    PubMed abstract
  28. Silverberg M, Leyden W, Stewart C, Ralston J, Horberg M, Carzasty S, Grothaus L, Catz S, Change in adherence to antiretrovirals after initial use of an electronic shared medical record among HIV-Infected individuals. Clinical Medicine & Research, 2012; 10(3): 144-145.  
    PubMed abstract
  29. Towner WJ, Xu L, Leyden WA, Horberg MA, Chao CR, Tang B, Klein DB, Hurley LB, Quesenberry CP, Jr., Silverberg MJ. The Effect of HIV Infection, Immunodeficiency, and Antiretroviral Therapy on the Risk of Hepatic Dysfunction. J Acquir Immune Defic Syndr. Jul 2012;60(3):321-327.
    PubMed abstract
  30. Horberg M, Hurley L, Towner W, Allerton M, Tang B, Catz S, Silverberg M, Quesenberry C. Determination of Optimized Multidisciplinary Care Team for Maximal Antiretroviral Therapy Adherence. J Acquir Immune Defic Syndr. Jun 1 2012;60(2):183-190.
    PubMed abstract
  31. Chao C, Tang B, Towner W, Silverberg MJ, Hurley L, Horberg M. Short-term clinical outcomes among treatment-experienced HIV-positive patients with early low level viremia. AIDS Patient Care STDS. May 2012;26(5):253-255.
    PubMed abstract
  32. Chao C, Tang B, Hurley L, Silverberg MJ, Towner W, Preciado M, Horberg M. Risk Factors for Short-Term Virologic Outcomes Among HIV-Infected Patients Undergoing Regimen Switch of Combination Antiretroviral Therapy. Clinical Medicine & Research. 2012:10(3): 156.
    PubMed abstract
  33. Silverberg MJ, Chao C, Leyden WA, Xu L, Horberg MA, Klein D, Towner WJ, Dubrow R, Quesenberry CP, Jr., Neugebauer RS, Abrams DI. HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol Biomarkers Prev. Dec 2011;20(12):2551-2559.
    PubMed abstract
  34. Shindel AW, Horberg MA, Smith JF, Breyer BN. Sexual dysfunction, HIV, and AIDS in men who have sex with men. AIDS Patient Care STDS. Jun 2011;25(6):341-349.
    PubMed abstract
  35. Schwarz EB, Postlethwaite D, Hung YY, Lantzman E, Armstrong MA, Horberg MA. Provision of Contraceptive Services to Women with Diabetes Mellitus. J Gen Intern Med. Feb 2012;27(2):196-201
    PubMed abstract
  36. Potter MB, Somkin CP, Ackerson LM, Gomez V, Dao T, Horberg MA, Walsh JM. The FLU-FIT program: an effective colorectal cancer screening program for high volume flu shot clinics. Am J Manag Care. 2011;17(8):577-583.
    PubMed abstract
  37. Horberg M, Hurley L, Towner W, Gambatese R, Klein D, Antoniskis D, Weinberg W, Kadlecik P, Remmers C, Dobrinich R, Quesenberry C, Silverberg M, Johnson M. HIV quality performance measures in a large integrated health care system. AIDS Patient Care STDS. Jan 2011;25(1):21-28.
    PubMed abstract
  38. Gallant JE, Adimora AA, Carmichael JK, Horberg M, Kitahata M, Quinlivan EB, Raper JL, Selwyn P, Williams SB. Essential components of effective HIV care: a policy paper of the HIV Medicine Association of the Infectious Diseases Society of America and the Ryan White Medical Providers Coalition. Clin Infect Dis. Dec 2011;53(11):1043-1050. [Epub ahead of print].
    PubMed abstract
  39. Chao C, Xu L, Abrams DI, Towner WJ, Horberg MA, Leyden WA, Silverberg MJ. HMG-CoA reductase inhibitors (statins) use and risk of non-Hodgkin lymphoma in HIV-positive persons. Aids. Sep 10 2011;25(14):1771-1777.
    PubMed abstract
  40. Breyer BN, Van den Eeden SK, Horberg MA, Eisenberg ML, Deng DY, Smith JF, Shindel AW. HIV status is an independent risk factor for reporting lower urinary tract symptoms. J Urol. May 2011;185(5):1710-1715.
    PubMed abstract
  41. Abraham AG, Lau B, Deeks S, Moore RD, Zhang J, Eron J, Harrigan R, Gill MJ, Kitahata M, Klein M, Napravnik S, Rachlis A, Rodriguez B, Rourke S, Benson C, Bosch R, Collier A, Gebo K, Goedert J, Hogg R, Horberg M, Jacobson L, Justice A, Kirk G, Martin J, McKaig R, Silverberg M, Sterling T, Thorne J, Willig J, Gange SJ. Missing data on the estimation of the prevalence of accumulated human immunodeficiency virus drug resistance in patients treated with antiretroviral drugs in north america. Am J Epidemiol. Sep 15 2011;174(6):727-735.
    PubMed abstract
  42. Sterling TR, Lau B, Zhang J, Freeman A, Bosch RJ, Brooks JT, Deeks SG, French A, Gange S, Gebo KA, John Gill M, Horberg MA, Jacobson LP, Kirk GD, Kitahata MM, Klein MB, Martin JN, Rodriguez B, Silverberg MJ, Willig JH, Eron JJ, Goedert JJ, Hogg RS, Justice AC, McKaig RG, Napravnik S, Thorne J, Moore RD. Risk factors for tuberculosis after highly active antiretroviral therapy initiation in the United States and Canada: implications for tuberculosis screening. J Infect Dis. Sep 15 2011;204(6):893-901.
    PubMed abstract
  43. Mosen D, Horberg M, Roblin D, Gullion C, Meenan R, Leyden W, Hu W. Effect of once-daily FDC treatment era on initiation of cART. . HIV/AIDS-Research and Palliative Care. 2010;2:19-26.
  44. Horberg MA, Ranatunga DK, Quesenberry CP, Klein DB, Silverberg MJ. Syphilis epidemiology and clinical outcomes in HIV-infected and HIV-uninfected patients in Kaiser Permanente Northern California. Sex Transm Dis. Jan 2010;37(1):53-58.
    PubMed abstract
  45. Horberg MA, Aberg JA, Cheever LW, Renner P, O’Brien Kaleba E, Asch SM. Development of national and multiagency HIV care quality measures. Clin Infect Dis. Sep 15 2010;51(6):732-738.
    PubMed abstract
  46. Horberg M, Tang B, Towner W, Silverberg M, Bersoff-Matcha S, Hurley L, Chang J, Blank J, Quesenberry C, Jr., Klein D. Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients. J Acquir Immune Defic Syndr. Jan 2010;53(1):62-69.
    PubMed abstract
  47. Horberg M, klein D. An update on the use of Atripla in the Treatment of HIV in the US. HIV-Research and Palliative Care. 2010;2:135-140.
  48. Chao C, Xu L, Abrams D, Leyden W, Horberg M, Towner W, Klein D, Tang B, Silverberg M. Survival of non-Hodgkin lymphoma patients with and without HIV infection in the era of combined antiretroviral therapy. Aids. Jul 17 2010;24(11):1765-1770.
    PubMed abstract
  49. Althoff KN, Gebo KA, Gange SJ, Klein MB, Brooks JT, Hogg RS, Bosch RJ, Horberg MA, Saag MS, Kitahata MM, Eron JJ, Napravnik S, Rourke SB, Gill MJ, Rodriguez B, Sterling TR, Deeks SG, Martin JN, Jacobson LP, Kirk GD, Collier AC, Benson CA, Silverberg MJ, Goedert JJ, McKaig RG, Thorne J, Rachlis A, Moore RD, Justice AC. CD4 count at presentation for HIV care in the United States and Canada: are those over 50 years more likely to have a delayed presentation? AIDS Res Ther. 2010;7:45.
    PubMed abstract
  50. Althoff KN, Gange SJ, Klein MB, Brooks JT, Hogg RS, Bosch RJ, Horberg MA, Saag MS, Kitahata MM, Justice AC, Gebo KA, Eron JJ, Rourke SB, Gill MJ, Rodriguez B, Sterling TR, Calzavara LM, Deeks SG, Martin JN, Rachlis AR, Napravnik S, Jacobson LP, Kirk GD, Collier AC, Benson CA, Silverberg MJ, Kushel M, Goedert JJ, McKaig RG, Van Rompaey SE, Zhang J, Moore RD. Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis. Jun 1 2010;50(11):1512-1520.
    PubMed abstract
  51. Towner W, Klein D, Kerrigan HL, Follansbee S, Yu K, Horberg M. Virologic outcomes of changing enfuvirtide to raltegravir in HIV-1 patients well controlled on an enfuvirtide based regimen: 24-week results of the CHEER study. J Acquir Immune Defic Syndr. Aug 1 2009;51(4):367-373.
    PubMed abstract
  52. Silverberg MJ, Leyden W, Quesenberry CP, Jr., Horberg MA. Race/ethnicity and risk of AIDS and death among HIV-infected patients with access to care. J Gen Intern Med. Sep 2009;24(9):1065-1072.
    PubMed abstract
  53. Silverberg MJ, Leyden W, Hurley L, Go AS, Quesenberry CP, Jr., Klein D, Horberg MA. Response to newly prescribed lipid-lowering therapy in patients with and without HIV infection. Ann Intern Med. Mar 3 2009;150(5):301-313.
    PubMed abstract
  54. Silverberg MJ, Chao C, Leyden WA, Xu L, Tang B, Horberg MA, Klein D, Quesenberry CP, Jr., Towner WJ, Abrams DI. HIV infection and the risk of cancers with and without a known infectious cause. Aids. Nov 13 2009;23(17):2337-2345.
    PubMed abstract
  55. Rhee SY, Fessel WJ, Liu TF, Marlowe NM, Rowland CM, Rode RA, Vandamme AM, Van Laethem K, Brun-Vezinet F, Calvez V, Taylor J, Hurley L, Horberg M, Shafer RW. Predictive value of HIV-1 genotypic resistance test interpretation algorithms. J Infect Dis. Aug 1 2009;200(3):453-463.
    PubMed abstract
  56. Klein DB, Hurley LB, Horberg MA, Silverberg MJ, Follansbee SE, Flamm JA, Green GM. Increased rates of appendicitis in HIV-infected men: 1991-2005. J Acquir Immune Defic Syndr. Sep 1 2009;52(1):139-140.
    PubMed abstract
  57. Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, Hogg RS, Deeks SG, Eron JJ, Brooks JT, Rourke SB, Gill MJ, Bosch RJ, Martin JN, Klein MB, Jacobson LP, Rodriguez B, Sterling TR, Kirk GD, Napravnik S, Rachlis AR, Calzavara LM, Horberg MA, Silverberg MJ, Gebo KA, Goedert JJ, Benson CA, Collier AC, Van Rompaey SE, Crane HM, McKaig RG, Lau B, Freeman AM, Moore RD. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. Apr 30 2009;360(18):1815-1826.
    PubMed abstract
  58. Deeks SG, Gange SJ, Kitahata MM, Saag MS, Justice AC, Hogg RS, Eron JJ, Brooks JT, Rourke SB, Gill MJ, Bosch RJ, Benson CA, Collier AC, Martin JN, Klein MB, Jacobson LP, Rodriguez B, Sterling TR, Kirk GD, Napravnik S, Rachlis AR, Calzavara LM, Horberg MA, Silverberg MJ, Gebo KA, Kushel MB, Goedert JJ, McKaig RG, Moore RD. Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. Clin Infect Dis. Nov 15 2009;49(10):1582-1590.
    PubMed abstract
  59. Horberg MA, Silverberg MJ, Hurley LB, Towner WJ, Klein DB, Bersoff-Matcha S, Weinberg WG, Antoniskis D, Mogyoros M, Dodge WT, Dobrinich R, Quesenberry CP, Kovach DA. Effects of depression and selective serotonin reuptake inhibitor use on adherence to highly active antiretroviral therapy and on clinical outcomes in HIV-infected patients. J Acquir Immune Defic Syndr. Mar 1 2008;47(3):384-390.
    PubMed abstract
  60. Horberg M, Silverberg M, Hurley L, Delorenze G, Quesenberry C. Influence of prior antiretroviral experience on adherence and responses to new highly active antiretroviral therapy regimens. AIDS Patient Care STDS. Apr 2008;22(4):301-312.
    PubMed abstract
  61. Horberg M, Klein D, Hurley L, Silverberg M, Towner W, Antoniskis D, Kovach D, Mogyoros M, Blake W, Dobrinich R, Dodge W. Efficacy and safety of ritonavir-boosted and unboosted atazanavir among antiretroviral-naive patients. HIV Clin Trials. Nov-Dec 2008;9(6):367-374.
    PubMed abstract
  62. Silverberg MJ, Leyden W, Horberg MA, DeLorenze GN, Klein D, Quesenberry CP, Jr. Older age and the response to and tolerability of antiretroviral therapy. Arch Intern Med. Apr 9 2007;167(7):684-691.
    PubMed abstract
  63. Horberg MA, Hurley LB, Silverberg MJ, Kinsman CJ, Quesenberry CP. Effect of clinical pharmacists on utilization of and clinical response to antiretroviral therapy. J Acquir Immune Defic Syndr. Apr 15 2007;44(5):531-539.
    PubMed abstract
  64. Gange SJ, Kitahata MM, Saag MS, Bangsberg DR, Bosch RJ, Brooks JT, Calzavara L, Deeks SG, Eron JJ, Gebo KA, Gill MJ, Haas DW, Hogg RS, Horberg MA, Jacobson LP, Justice AC, Kirk GD, Klein MB, Martin JN, McKaig RG, Rodriguez B, Rourke SB, Sterling TR, Freeman AM, Moore RD. Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol. Apr 2007;36(2):294-301.
    PubMed abstract
  65. Cheever LW, Lubinski C, Horberg M, Steinberg JL. Ensuring access to treatment for HIV infection. Clin Infect Dis. Dec 15 2007;45 Suppl 4:S266-274.
    PubMed abstract
  66. Mitsuya Y, Winters MA, Fessel WJ, Rhee SY, Slome S, Flamm J, Horberg M, Hurley L, Klein D, Shafer RW. HIV-1 drug resistance genotype results in patients with plasma samples with HIV-1 RNA levels less than 75 copies/mL. J Acquir Immune Defic Syndr. Sep 2006;43(1):56-59.
    PubMed abstract
  67. Mitsuya Y, Winters MA, Fessel WJ, Rhee SY, Hurley L, Horberg M, Schiffer CA, Zolopa AR, Shafer RW. N88D facilitates the co-occurrence of D30N and L90M and the development of multidrug resistance in HIV type 1 protease following nelfinavir treatment failure. AIDS Res Hum Retroviruses. Dec 2006;22(12):1300-1305.
    PubMed abstract
  68. Horberg MA, Hurley LB, Klein DB, Follansbee SE, Quesenberry C, Flamm JA, Green GM, Luu T. Surgical outcomes in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy. Arch Surg. Dec 2006;141(12):1238-1245.
    PubMed abstract
  69. Horberg M, Antoniskis D, Bersoff-Matcha S, Hurley L, Klein D, Kovach D, Mogyoros M, Towner W, Weinberg W. Perceptions of human immunodeficiency virus testing services among HIV-positive persons not in medical care. Sex Transm Dis. Jul 2006;33(7):464; author reply 465.
    PubMed abstract

  1. Optimizing Multidisciplinary HIV Care Team for Maximal HAART Adherence (1R21MH085553-01A1)
    Goal:
    Retrospective cohort study to determine optimized HIV multidisciplinary care team to maximize HAART adherence and other HIV outcomes and minimize urgent care utilization.
    Funder:
    National Institutes of Mental Health
    Principal Investigator:
    Michael Horberg
  2. Preventive Health Index for HIV-Infected Population
    Goal:
    Retrospective study to assess the impact of preventive health services on the ongoing and long term care of HIV-infected patients in KP. This work will extend the original work on the preventive health index by Tom Vogt, PhD. Data from KPNC, KPSC, KPNW, and KPGA will be utilized.
    Funder:
    NIH (AHRQ R01)
    Principal Investigator:
    Michael Horberg
  3. HIV and HCV Co-Infection and Care Implications
    Goal:
    This study explores using retrospective data from KPMA the cost and effectiveness implications of care for patients with the HCV mono-infection and the HIV/HCV co-infection.
    Funder:
    NIH (NIAID R01)
    Site Principal Investigator:
    Michael Horberg
  4. Kaiser Permanente HIV Quality Improvement and Performance Program
    Goal:
    We seek to determine quantitative measures of HIV care and outcomes in Kaiser Permanente. We seek to then initiate quality improvement programs where we determine there are opportunities for improvement.
    Funder
    : Care Management Institute/The Permanente Federation/Kaiser Health Plans
    Project and Overall Clinical Leader:
    Michael Horberg
  5. KPMA HIV Registry
    Goal:
    Develop the HIV registry that closely aligns with the other KP regions’ case definitions. This registry will be used to identify populations for potential research studies, clinical trials, and clinical applications as required.
    Funder:
    Kaiser Permanente Mid-Atlantic Community Benefits
    Principal Investigator:
    Michael Horberg
  6. North American AIDS Cohorts Collaboration on Research and Design (NA-ACCORD)
    Goal:
    This is the North America response to IeDEA, and for which Kaiser Permanente Northern California participates. It is a collaborative cohort compendium and analysis for purposes of achieving sufficient power to address issues that could not be adequately addressed by single cohorts.
    Funder:
    National Institute of Allergy and Infectious Diseases
    Site Principal Investigator
    : Michael Horberg
  7. Observational Post-Authorization Study of Patients Treated with Raltegravir
    Goal:
    Five year surveillance data study to assess safety of new antiretroviral medication raltegravir, with comparisons to rates among similar HIV-infected patients taking antiretroviral medications other than raltegravir.
    Funder:
    Merck
    Principal Investigator
    : Michael Horberg
  8. Impact of Missed Office Visits on HIV Outcomes and Mortality
    Goal:
    A retrospective cohort study investigating the impact of missed office in the first twelve months after HIV diagnosis on later mortality, treatment adherence, and other HIV-related health outcomes. Comparisons will be made to the previously published work at University of Alabama, Birmingham.
    Funder:
    KPNC Community Benefits Research Fund
    Principal Investigator:
    Michael Horberg
  9. Considerations of Emerging Issues in the Treatment of HIV (“CEITH”)
    Goal:
    Retrospective cohort study investigating issues of low level viremia in patients on antiretroviral therapy, advanced treatment failure in HIV-infected patients, and uptake of a new antiretroviral drug class in a closed healthcare system.
    Funder:
    Merck
    Principal Investigator:
    Michael Horberg
  10. KPMA Hepatitis Registries
    Goal:
    Development of the hepatitis B and C registries are critical to ongoing research efforts for KPMA. The hepatitis C registry case finding and registry population is ongoing, with development of hepatitis B and cirrhosis registries next. Both epidemiologic and clinical applications are anticipated.
    Funder:
    Kaiser Permanente Mid-Atlantic Community Benefits
    Principal Investigator (MAPRI):
    Michael Horberg
  11. KPMA Sickle Cell Disease Registry
    Goal:
    Develop a sickle cell disease registry that closely aligns with the other KP regions’ case definitions. The registry will be used to facilitate future IRB-approved research based on known cases within the registry, to improve care, and to enhance clinical decision making.  
    Funder: Kaiser Permanente Mid-Atlantic Community Benefits
    Principal Investigator (MAPRI):
    Michael Horberg